Market Cap 1.13B
Revenue (ttm) 727.33M
Net Income (ttm) -108.03M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -14.85%
Debt to Equity Ratio 0.00
Volume 1,721,000
Avg Vol 2,093,054
Day's Range N/A - N/A
Shares Out 130.21M
Stochastic %K 23%
Beta 1.81
Analysts Strong Sell
Price Target $15.05

Company Profile

NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories. It also provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the pr...

Industry: Diagnostics & Research
Sector: Healthcare
Phone: 239 768 0600
Fax: 239 690 4237
Address:
9490 NeoGenomics Way, Fort Myers, United States
EarningsInsider
EarningsInsider May. 12 at 2:45 PM
https://www.marketbeat.com/earnings/reports/2026-5-12-neo-performance-materials-inc-stock-1/ $NEO Neo Performance Materials Earnings Trans
0 · Reply
proof851
proof851 May. 6 at 12:45 PM
$NEO long term holder
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser May. 5 at 3:11 PM
$NEO RSI: 54.24, MACD: 0.1950 Vol: 0.50, MA20: 8.46, MA50: 8.45 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
GordoHLYK13
GordoHLYK13 May. 1 at 9:07 PM
$GNS $HLYK $STUB $NEO Good luck everyone in your investments. These are mine with my fun money, separate from my Nationwide Pro account and FRS pension. $GNS 10k shares average $.2741 * Arbitration win: 7.4M shares returned + $8M cash * 2026 outlook: $20$22M revenue, potential positive adjusted EBITDA * AI education expansion + “Space Capsule” rollout $STUB (StubHub) 3k shares average $6.25 * Q1 2026 earnings scheduled for May 13, 2026 (after close) * Expanding globally in Asia and Latin America $NEO (NeoGenomics) 3k shares $7.97 * Raised 2026 revenue guidance to ~$797$803M * New cancer test (RaDaR ST MRD) targeting large market * New insurance coverage boosting demand $HLYK (HealthLynked) 8k shares $5.54 * Working toward NASDAQ listing via $7M offering * Launching AI healthcare assistant (ARi) for patient management Just sharing what I’m personally positioned in—nothing more.
0 · Reply
GordoHLYK13
GordoHLYK13 May. 1 at 4:12 PM
$GNS $NEO $STUB My total gains so far in few weeks $GNS is just starting
0 · Reply
GordoHLYK13
GordoHLYK13 May. 1 at 1:23 PM
$GNS check out Genius trying to be my Friday anchor next to $NEO and $STUB Pre market todays gains
0 · Reply
GordoHLYK13
GordoHLYK13 Apr. 30 at 11:06 PM
$GNS I don’t trade ego or keep score on comment sections — I trade setups. I move on the same way every time: lock in profits when they’re there, rotate out of noise, and re-enter when I see asymmetric upside with real catalysts and structure behind it like $NEO and $STUB that’s how you stay in the game long term — not by marrying a ticker or arguing online. You can scroll posts all you want, but that doesn’t change the fact that disciplined traders survive cycles while emotional ones chase narratives. I’m here for the next move, not the last argument.
0 · Reply
carminefox
carminefox Apr. 30 at 2:39 PM
$NEO good job with the earnings again! Just waiting on that buyout offer now.
0 · Reply
GordoHLYK13
GordoHLYK13 Apr. 30 at 11:10 AM
$GNS, $NEO , and $STUB—all in play. $GNS needs to step it up and keep pressure on. My portfolio is up 82% since last year and—added $GNS9K shares yesterday, just the start and feeling good This whole portfolio is built for upside. Let’s see it work. Not a big deal but feeling blessed
1 · Reply
Hashstockw
Hashstockw Apr. 30 at 4:01 AM
$NEO and this is the second analyst in the last few days. The stock is still severely undervalued. https://www.marketbeat.com/instant-alerts/td-cowen-issues-positive-forecast-for-neogenomics-nasdaqneo-stock-price-2026-04-29/
0 · Reply
Latest News on NEO
NeoGenomics price target lowered to $11 from $13 at BofA

2026-04-29T16:45:29.000Z - 13 days ago

NeoGenomics price target lowered to $11 from $13 at BofA


NeoGenomics price target raised to $14 from $13 at TD Cowen

2026-04-29T13:42:05.000Z - 13 days ago

NeoGenomics price target raised to $14 from $13 at TD Cowen


NeoGenomics upgraded to Buy from Hold at Benchmark

2026-04-29T10:26:48.000Z - 14 days ago

NeoGenomics upgraded to Buy from Hold at Benchmark


NeoGenomics reports Q1 adjusted EPS 1c, consensus 0c

2026-04-28T21:39:08.000Z - 14 days ago

NeoGenomics reports Q1 adjusted EPS 1c, consensus 0c


NeoGenomics Earnings Call Transcript: Q1 2026

Apr 28, 2026, 4:30 PM EDT - 14 days ago

NeoGenomics Earnings Call Transcript: Q1 2026


NeoGenomics Reports First Quarter 2026 Results

Apr 28, 2026, 4:05 PM EDT - 14 days ago

NeoGenomics Reports First Quarter 2026 Results


NeoGenomics expands access to full oncology testing portfolio

2026-04-23T11:26:56.000Z - 20 days ago

NeoGenomics expands access to full oncology testing portfolio


NeoGenomics PanTracer LBx test receives Medicare coverage

2026-03-16T11:28:54.000Z - 2 months ago

NeoGenomics PanTracer LBx test receives Medicare coverage


NeoGenomics to Participate in Upcoming Investor Conferences

Feb 18, 2026, 7:05 AM EST - 3 months ago

NeoGenomics to Participate in Upcoming Investor Conferences


NeoGenomics Earnings Call Transcript: Q4 2025

Feb 17, 2026, 8:30 AM EST - 3 months ago

NeoGenomics Earnings Call Transcript: Q4 2025


NeoGenomics sees FY26 adjusted EPS 16c-21c, consensus 19c

2026-02-17T12:45:49.000Z - 3 months ago

NeoGenomics sees FY26 adjusted EPS 16c-21c, consensus 19c


NeoGenomics reports Q4 adjusted EPS 6c, consensus 4c

2026-02-17T12:40:53.000Z - 3 months ago

NeoGenomics reports Q4 adjusted EPS 6c, consensus 4c


NeoGenomics Reports Fourth Quarter and Full Year 2025 Results

Feb 17, 2026, 7:05 AM EST - 3 months ago

NeoGenomics Reports Fourth Quarter and Full Year 2025 Results


NeoGenomics price target raised to $16 from $14 at TD Cowen

2026-01-07T14:15:51.000Z - 4 months ago

NeoGenomics price target raised to $16 from $14 at TD Cowen


NeoGenomics price target raised to $13 from $11 at BofA

2025-12-15T15:40:44.000Z - 5 months ago

NeoGenomics price target raised to $13 from $11 at BofA


NeoGenomics to Present New ctDNA Research at SABCS 2025

Dec 10, 2025, 7:05 AM EST - 5 months ago

NeoGenomics to Present New ctDNA Research at SABCS 2025


NeoGenomics Transcript: Stephens Annual Investment Conference

Nov 19, 2025, 2:00 PM EST - 6 months ago

NeoGenomics Transcript: Stephens Annual Investment Conference


NeoGenomics Earnings Call Transcript: Q3 2025

Oct 28, 2025, 8:30 AM EDT - 7 months ago

NeoGenomics Earnings Call Transcript: Q3 2025


NeoGenomics Reports Third Quarter 2025 Results

Oct 28, 2025, 7:05 AM EDT - 7 months ago

NeoGenomics Reports Third Quarter 2025 Results


NeoGenomics Earnings Call Transcript: Q2 2025

Jul 29, 2025, 8:30 AM EDT - 10 months ago

NeoGenomics Earnings Call Transcript: Q2 2025


NeoGenomics Reports Second Quarter 2025 Results

Jul 29, 2025, 7:05 AM EDT - 10 months ago

NeoGenomics Reports Second Quarter 2025 Results


NeoGenomics Appoints Dr. Marjorie Green to Board of Directors

Jun 24, 2025, 7:05 AM EDT - 11 months ago

NeoGenomics Appoints Dr. Marjorie Green to Board of Directors


NeoGenomics Pays Off 1.25% Convertible Senior Notes

May 1, 2025, 7:05 AM EDT - 1 year ago

NeoGenomics Pays Off 1.25% Convertible Senior Notes


NeoGenomics Earnings Call Transcript: Q1 2025

Apr 29, 2025, 8:30 AM EDT - 1 year ago

NeoGenomics Earnings Call Transcript: Q1 2025


NeoGenomics Reports First Quarter 2025 Results

Apr 29, 2025, 7:30 AM EDT - 1 year ago

NeoGenomics Reports First Quarter 2025 Results


NeoGenomics Completes Acquisition of Pathline

Apr 7, 2025, 7:05 AM EDT - 1 year ago

NeoGenomics Completes Acquisition of Pathline


NeoGenomics Earnings Call Transcript: Q4 2024

Feb 18, 2025, 8:30 AM EST - 1 year ago

NeoGenomics Earnings Call Transcript: Q4 2024


NeoGenomics Reports Fourth Quarter and Full Year 2024 Results

Feb 18, 2025, 7:05 AM EST - 1 year ago

NeoGenomics Reports Fourth Quarter and Full Year 2024 Results


NeoGenomics Announces Chief Executive Officer Succession

Jan 10, 2025, 7:05 AM EST - 1 year ago

NeoGenomics Announces Chief Executive Officer Succession


EarningsInsider
EarningsInsider May. 12 at 2:45 PM
https://www.marketbeat.com/earnings/reports/2026-5-12-neo-performance-materials-inc-stock-1/ $NEO Neo Performance Materials Earnings Trans
0 · Reply
proof851
proof851 May. 6 at 12:45 PM
$NEO long term holder
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser May. 5 at 3:11 PM
$NEO RSI: 54.24, MACD: 0.1950 Vol: 0.50, MA20: 8.46, MA50: 8.45 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
GordoHLYK13
GordoHLYK13 May. 1 at 9:07 PM
$GNS $HLYK $STUB $NEO Good luck everyone in your investments. These are mine with my fun money, separate from my Nationwide Pro account and FRS pension. $GNS 10k shares average $.2741 * Arbitration win: 7.4M shares returned + $8M cash * 2026 outlook: $20$22M revenue, potential positive adjusted EBITDA * AI education expansion + “Space Capsule” rollout $STUB (StubHub) 3k shares average $6.25 * Q1 2026 earnings scheduled for May 13, 2026 (after close) * Expanding globally in Asia and Latin America $NEO (NeoGenomics) 3k shares $7.97 * Raised 2026 revenue guidance to ~$797$803M * New cancer test (RaDaR ST MRD) targeting large market * New insurance coverage boosting demand $HLYK (HealthLynked) 8k shares $5.54 * Working toward NASDAQ listing via $7M offering * Launching AI healthcare assistant (ARi) for patient management Just sharing what I’m personally positioned in—nothing more.
0 · Reply
GordoHLYK13
GordoHLYK13 May. 1 at 4:12 PM
$GNS $NEO $STUB My total gains so far in few weeks $GNS is just starting
0 · Reply
GordoHLYK13
GordoHLYK13 May. 1 at 1:23 PM
$GNS check out Genius trying to be my Friday anchor next to $NEO and $STUB Pre market todays gains
0 · Reply
GordoHLYK13
GordoHLYK13 Apr. 30 at 11:06 PM
$GNS I don’t trade ego or keep score on comment sections — I trade setups. I move on the same way every time: lock in profits when they’re there, rotate out of noise, and re-enter when I see asymmetric upside with real catalysts and structure behind it like $NEO and $STUB that’s how you stay in the game long term — not by marrying a ticker or arguing online. You can scroll posts all you want, but that doesn’t change the fact that disciplined traders survive cycles while emotional ones chase narratives. I’m here for the next move, not the last argument.
0 · Reply
carminefox
carminefox Apr. 30 at 2:39 PM
$NEO good job with the earnings again! Just waiting on that buyout offer now.
0 · Reply
GordoHLYK13
GordoHLYK13 Apr. 30 at 11:10 AM
$GNS, $NEO , and $STUB—all in play. $GNS needs to step it up and keep pressure on. My portfolio is up 82% since last year and—added $GNS9K shares yesterday, just the start and feeling good This whole portfolio is built for upside. Let’s see it work. Not a big deal but feeling blessed
1 · Reply
Hashstockw
Hashstockw Apr. 30 at 4:01 AM
$NEO and this is the second analyst in the last few days. The stock is still severely undervalued. https://www.marketbeat.com/instant-alerts/td-cowen-issues-positive-forecast-for-neogenomics-nasdaqneo-stock-price-2026-04-29/
0 · Reply
IN0V8
IN0V8 Apr. 29 at 4:40 PM
$NEO Buy Benchmark raises to buy from hold Leerink Partners raises target price to $25.00 from $12.00 Leerink Partners raises to outperform from market ?perform
0 · Reply
GordoHLYK13
GordoHLYK13 Apr. 29 at 3:38 PM
1 · Reply
GetVector
GetVector Apr. 29 at 12:49 PM
Vector Intelligence (VI) is an algorithm designed to predict potential outsized intraday moves. VI will select up to 4 stocks per day. Today's VI stocks: $BE, $NEO, $STX, $VRNS.
0 · Reply
GordoHLYK13
GordoHLYK13 Apr. 29 at 11:36 AM
0 · Reply
GordoHLYK13
GordoHLYK13 Apr. 29 at 11:17 AM
$NEO $EXAS $GH $NTRA $NEO move is no pump n dump — this is what a real fundamental breakout looks like. 🚀 NEO ripping premarket is a direct reaction to legit catalysts, not hype: 🔥 Q1 Earnings Beat • Revenue came in at $187M, beating Wall Street • Clinical revenue up 14% YoY • High-margin NGS revenue exploded 26% • Management RAISED 2026 guidance to $797M$803M 🔥 Analyst Upgrades Rolling In • Leerink upgraded to Outperform and doubled PT from $12 to $25 • Benchmark also upgraded to Buy 🔥 MolDX Approval PanTracer liquid biopsy getting reimbursement support is a game changer — opens the door for recurring revenue and lowers risk big time. 💰 Heavy volume + better numbers + raised guidance + analysts chasing = smart money stepping in. This isn’t a pump… this is institutions repricing NEO higher. 📈
0 · Reply
ValueVester
ValueVester Apr. 28 at 10:23 PM
$NEO Finally. A quarter we can sink our teeth in.
0 · Reply
GordoHLYK13
GordoHLYK13 Apr. 28 at 9:35 PM
$NEO $NEO just dropped a strong Q1 and bulls should be paying attention. 🔥 • Revenue beat at $187M, up 11% YoY • Core Clinical business growing strong at +14% • High-margin NGS exploding +26% • Full-year guidance RAISED to $797M-$803M • EBITDA up 27% to $9M • Adjusted net income turned positive 💰 • RaDaR ST launch opens a $20B market opportunity Yes, Pharma softness exists, but the money maker clinical side is carrying hard. Flat after-hours means Wall Street may still be sleeping on this one. If growth keeps stacking, $NEO could wake people up fast. 🦈📈
0 · Reply
AnyMonkey
AnyMonkey Apr. 28 at 9:31 PM
$NEO ok, ok earnings not bad. lets get moving again.
1 · Reply
StocktwitsEarnings
StocktwitsEarnings Apr. 28 at 9:06 PM
$NEO Q1 '26 Earnings Results & Recap • Reported GAAP EPS of -$0.13 up 35.00% YoY • Reported revenue of $186.67M up 11.09% YoY • NeoGenomics anticipates capital expenditures for the year ending December 31, 2026, to be in the range of $30.0 million to $35.0 million, funded by cash and financing to support business growth.
0 · Reply
GordoHLYK13
GordoHLYK13 Apr. 28 at 8:04 PM
$CYCU $NEO $STUB The Nasdaq compliance clock has officially been reset. Bulls held the $1 close, pressure eased, and $CYCU just bought itself breathing room. Now it’s about stacking strength from here. 🔥
0 · Reply
GordoHLYK13
GordoHLYK13 Apr. 28 at 8:03 PM
$CYCU $NEO $STUB $CYCU closing at $1.00 is a psychological and strategic win. What it means: • Holds the dollar mark – That level matters because stocks under $1 often face compliance pressure and trader fear. Closing at $1 helps calm that noise. • Momentum signal – Buyers defended the line into the close, showing demand instead of collapse. • Confidence boost – After fake-news drama and volatility, closing at $1 says the market may be starting to trust the real story again. • Sets up next move – If it can stack closes above $1, traders may target higher resistance zones next. Bullish $CYCU just slammed the door at $1.00 — that’s more than a number, that’s a statement. Bears wanted sub-$1 fear, bulls held the line. With a $122M backlog, new contracts rolling in, and CEO fighting misinformation, this could be the first brick in a stronger reversal. Now the game is simple: hold $1 and hunt higher. 🐂🔥
0 · Reply
GordoHLYK13
GordoHLYK13 Apr. 28 at 7:25 PM
$NEO $STUB $CYCU Three great reasons why I’m holding CYCU, STUB, and NeoGenomics ($NEO) today: 1. CYCU – Momentum is building. Fresh news dropped with a $6M contract win and backlog now at $112M, showing real revenue visibility. For a microcap, that’s serious fuel if volume stays hot. 2. STUB – Undervalued setups can wake up fast when traders rotate into low-float/value names. Sometimes patience pays before the crowd notices. 3. NeoGenomics ($NEO) – Earnings today is the catalyst. If guidance is strong and oncology growth trends stay intact, this can re-rate quick. Market watches future outlook more than old numbers. My mindset: CYCU = breakout potential, STUB = sleeper value play, NEO = earnings catalyst. Holding all three because one headline can change everything today. Total gains so far and will get higher
0 · Reply